140 related articles for article (PubMed ID: 7479389)
1. Raloxifene (LY156758) produces antimetastatic responses and extends survival in the PAIII rat prostatic adenocarcinoma model.
Neubauer BL; Best KL; Counts DF; Goode RL; Hoover DM; Jones CD; Sarosdy MF; Shaar CJ; Tanzer LR; Merriman RL
Prostate; 1995 Oct; 27(4):220-9. PubMed ID: 7479389
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of PAIII rat prostatic adenocarcinoma growth and metastasis by a new diarylsulfonylurea antitumor agent, LY181984.
Neubauer BL; Merriman RL; Best KL; Goode RL; Sarosdy MF; Tanzer LR; Howbert JJ
J Urol; 1992 Feb; 147(2):500-4. PubMed ID: 1732631
[TBL] [Abstract][Full Text] [Related]
3. Comparative antitumor effects of hormonal ablation, estrogen agonist, estrogen cytotoxic derivative, and antiestrogen in the PAIII rat prostatic adenocarcinoma.
Neubauer BL; Best KL; Goode RL; Heiman ML; Hoover DM; Robertson DW; Sarosdy MF; Shaar CJ; Tanzer LR; Merriman RL
Cancer Res; 1992 Sep; 52(17):4663-71. PubMed ID: 1511432
[TBL] [Abstract][Full Text] [Related]
4. The selective estrogen receptor modulator trioxifene (LY133314) inhibits metastasis and extends survival in the PAIII rat prostatic carcinoma model.
Neubauer BL; McNulty AM; Chedid M; Chen K; Goode RL; Johnson MA; Jones CD; Krishnan V; Lynch R; Osborne HE; Graff JR
Cancer Res; 2003 Sep; 63(18):6056-62. PubMed ID: 14522935
[TBL] [Abstract][Full Text] [Related]
5. Metastatic spread of the PAIII prostatic adenocarcinoma after implantation in the tail of the rat.
Neubauer BL; Bemis KG; Best KL; Goode RL; Merriman RL; Smith GF; Tanzer LR; Hoover DM
Prostate; 1986; 8(3):265-76. PubMed ID: 3703746
[TBL] [Abstract][Full Text] [Related]
6. Endocrine and antiprostatic effects of raloxifene (LY156758) in the male rat.
Neubauer BL; Best KL; Clemens JA; Gates CA; Goode RL; Jones CD; Laughlin ME; Shaar CJ; Toomey RE; Hoover DM
Prostate; 1993; 23(3):245-62. PubMed ID: 8234067
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effect of warfarin on the metastasis of the PAIII prostatic adenocarcinoma in the rat.
Neubauer BL; Bemis KG; Best KL; Goode RL; Hoover DM; Smith GF; Tanzer LR; Merriman RL
J Urol; 1986 Jan; 135(1):163-6. PubMed ID: 3941458
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and antitumor properties of selenocoxib-1 against rat prostate adenocarcinoma cells.
Desai D; Sinha I; Null K; Wolter W; Suckow MA; King T; Amin S; Sinha R
Int J Cancer; 2010 Jul; 127(1):230-8. PubMed ID: 19918950
[TBL] [Abstract][Full Text] [Related]
9. PAIII prostate tumors express prostate specific antigen (PSA) in Lobund-Wistar rats.
Suckow MA; Wheeler J; Yan M
Can J Vet Res; 2009 Jan; 73(1):39-41. PubMed ID: 19337394
[TBL] [Abstract][Full Text] [Related]
10. Antagonism of androgen and estrogen effects in guinea pig seminal vesicle epithelium and fibromuscular stroma by keoxifene (LY156758).
Neubauer BL; Biser P; Jones CD; Mariotti A; Hoover DM; Thornton T; Thornton MO; Goode RL
Prostate; 1989; 15(3):273-86. PubMed ID: 2531383
[TBL] [Abstract][Full Text] [Related]
11. The selective estrogen receptor modulator, raloxifene: an overview of nonclinical pharmacology and reproductive and developmental testing.
Buelke-Sam J; Bryant HU; Francis PC
Reprod Toxicol; 1998; 12(3):217-21. PubMed ID: 9628546
[TBL] [Abstract][Full Text] [Related]
12. Antiproliferative and antimetastatic effects of gossypol on Dunning prostate cell-bearing Copenhagen rats.
Chang CJ; Ghosh PK; Hu YF; Brueggemeier RW; Lin YC
Res Commun Chem Pathol Pharmacol; 1993 Mar; 79(3):293-312. PubMed ID: 8480076
[TBL] [Abstract][Full Text] [Related]
13. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate.
Frolik CA; Bryant HU; Black EC; Magee DE; Chandrasekhar S
Bone; 1996 Jun; 18(6):621-7. PubMed ID: 8806005
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological ascorbic acid suppresses syngeneic tumor growth and metastases in hormone-refractory prostate cancer.
Pollard HB; Levine MA; Eidelman O; Pollard M
In Vivo; 2010; 24(3):249-55. PubMed ID: 20554995
[TBL] [Abstract][Full Text] [Related]
15. Vaccination against prostate cancer using a live tissue factor deficient cell line in Lobund-Wistar rats.
Heinrich JE; Pollard M; Wolter WA; Liang Z; Song H; Rosen ED; Suckow MA
Cancer Immunol Immunother; 2007 May; 56(5):725-30. PubMed ID: 16953436
[TBL] [Abstract][Full Text] [Related]
16. Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels.
Clemens JA; Bennett DR; Black LJ; Jones CD
Life Sci; 1983 Jun; 32(25):2869-75. PubMed ID: 6406781
[TBL] [Abstract][Full Text] [Related]
17. Tissue selective action of tamoxifen methiodide, raloxifene and tamoxifen on creatine kinase B activity in vitro and in vivo.
Sömjen D; Waisman A; Kaye AM
J Steroid Biochem Mol Biol; 1996 Dec; 59(5-6):389-96. PubMed ID: 9010344
[TBL] [Abstract][Full Text] [Related]
18. Type II [3H]estradiol binding site antagonists: inhibition of normal and malignant prostate cell growth and proliferation.
Markaverich BM; Alejandro MA
Int J Oncol; 1998 May; 12(5):1127-35. PubMed ID: 9538139
[TBL] [Abstract][Full Text] [Related]
19. E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse.
Wechter WJ; Leipold DD; Murray ED; Quiggle D; McCracken JD; Barrios RS; Greenberg NM
Cancer Res; 2000 Apr; 60(8):2203-8. PubMed ID: 10786685
[TBL] [Abstract][Full Text] [Related]
20. Methylseleninic acid downregulates hypoxia-inducible factor-1α in invasive prostate cancer.
Sinha I; Null K; Wolter W; Suckow MA; King T; Pinto JT; Sinha R
Int J Cancer; 2012 Mar; 130(6):1430-9. PubMed ID: 21500193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
